Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. (Q37936908)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

review article

1 reference

title

Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

M Girotra

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

R R Abraham

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

R B Erlich

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

22 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

9-18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21938486%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10620-011-1854-0

13 February 2020

exact match

0 references

cites work

Molecular genetics of gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Diagnosis and treatment of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Updated population-based review of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Current status of gastrointestinal carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Carcinoid--a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Clinical and in vitro studies of imatinib in advanced carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Neuroendocrine tumors. Peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Collagen XVIII/endostatin structure and functional role in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1854-0